Logo image of AYJ.DE

VALNEVA SE (AYJ.DE) Stock Fundamental Analysis

FRA:AYJ - Deutsche Boerse Ag - FR0004056851 - Common Stock - Currency: EUR

2.788  -0.1 (-3.46%)

Fundamental Rating

3

Taking everything into account, AYJ scores 3 out of 10 in our fundamental rating. AYJ was compared to 73 industry peers in the Biotechnology industry. Both the profitability and financial health of AYJ have multiple concerns. While showing a medium growth rate, AYJ is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year AYJ has reported negative net income.
AYJ had a negative operating cash flow in the past year.
In the past 5 years AYJ always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: AYJ reported negative operating cash flow in multiple years.
AYJ.DE Yearly Net Income VS EBIT VS OCF VS FCFAYJ.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

With an excellent Return On Assets value of 7.48%, AYJ belongs to the best of the industry, outperforming 86.30% of the companies in the same industry.
AYJ has a better Return On Equity (20.65%) than 89.04% of its industry peers.
Industry RankSector Rank
ROA 7.48%
ROE 20.65%
ROIC N/A
ROA(3y)-15.85%
ROA(5y)-14.17%
ROE(3y)-50.34%
ROE(5y)-55.45%
ROIC(3y)N/A
ROIC(5y)N/A
AYJ.DE Yearly ROA, ROE, ROICAYJ.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

The Profit Margin of AYJ (15.08%) is better than 84.93% of its industry peers.
AYJ's Gross Margin of 41.01% is in line compared to the rest of the industry. AYJ outperforms 58.90% of its industry peers.
AYJ's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 15.08%
GM 41.01%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.2%
GM growth 5Y-7.06%
AYJ.DE Yearly Profit, Operating, Gross MarginsAYJ.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 -60

More info and screens

3

2. Health

2.1 Basic Checks

AYJ does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AYJ has been increased compared to 1 year ago.
Compared to 5 years ago, AYJ has more shares outstanding
AYJ has a better debt/assets ratio than last year.
AYJ.DE Yearly Shares OutstandingAYJ.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
AYJ.DE Yearly Total Debt VS Total AssetsAYJ.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

AYJ has an Altman-Z score of -0.12. This is a bad value and indicates that AYJ is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.12, AYJ is in line with its industry, outperforming 49.32% of the companies in the same industry.
A Debt/Equity ratio of 1.06 is on the high side and indicates that AYJ has dependencies on debt financing.
AYJ's Debt to Equity ratio of 1.06 is in line compared to the rest of the industry. AYJ outperforms 43.84% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.06
Debt/FCF N/A
Altman-Z -0.12
ROIC/WACCN/A
WACC8.67%
AYJ.DE Yearly LT Debt VS Equity VS FCFAYJ.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

2.3 Liquidity

A Current Ratio of 2.61 indicates that AYJ has no problem at all paying its short term obligations.
The Current ratio of AYJ (2.61) is comparable to the rest of the industry.
A Quick Ratio of 2.14 indicates that AYJ has no problem at all paying its short term obligations.
The Quick ratio of AYJ (2.14) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.61
Quick Ratio 2.14
AYJ.DE Yearly Current Assets VS Current LiabilitesAYJ.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for AYJ have decreased strongly by -184.21% in the last year.
The Revenue has grown by 10.32% in the past year. This is quite good.
The Revenue has been growing slightly by 6.09% on average over the past years.
EPS 1Y (TTM)-184.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.63%
Revenue 1Y (TTM)10.32%
Revenue growth 3Y-21.31%
Revenue growth 5Y6.09%
Sales Q2Q%50.31%

3.2 Future

AYJ is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 119.91% yearly.
AYJ is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 24.84% yearly.
EPS Next Y-597.38%
EPS Next 2Y-69.87%
EPS Next 3Y119.91%
EPS Next 5YN/A
Revenue Next Year6.9%
Revenue Next 2Y17.55%
Revenue Next 3Y26.72%
Revenue Next 5Y24.84%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AYJ.DE Yearly Revenue VS EstimatesAYJ.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M
AYJ.DE Yearly EPS VS EstimatesAYJ.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.5 -0.5 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AYJ. In the last year negative earnings were reported.
Also next year AYJ is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AYJ.DE Price Earnings VS Forward Price EarningsAYJ.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AYJ.DE Per share dataAYJ.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

AYJ's earnings are expected to grow with 119.91% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-69.87%
EPS Next 3Y119.91%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AYJ!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VALNEVA SE

FRA:AYJ (5/30/2025, 7:00:00 PM)

2.788

-0.1 (-3.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/bmo
Earnings (Next)08-12 2025-08-12
Inst Owners29.31%
Inst Owner ChangeN/A
Ins Owners0.18%
Ins Owner ChangeN/A
Market Cap233.00M
Analysts83.33
Price Target7.49 (168.65%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-31.52%
Min EPS beat(2)-115.24%
Max EPS beat(2)52.2%
EPS beat(4)2
Avg EPS beat(4)-8.58%
Min EPS beat(4)-115.24%
Max EPS beat(4)72.74%
EPS beat(8)4
Avg EPS beat(8)-10.16%
EPS beat(12)5
Avg EPS beat(12)-55.58%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.5%
Min Revenue beat(2)-4.78%
Max Revenue beat(2)1.77%
Revenue beat(4)1
Avg Revenue beat(4)-7.74%
Min Revenue beat(4)-14.39%
Max Revenue beat(4)1.77%
Revenue beat(8)4
Avg Revenue beat(8)-2.47%
Revenue beat(12)6
Avg Revenue beat(12)43.18%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.55%
PT rev (3m)-3.13%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-45.45%
EPS NY rev (1m)0%
EPS NY rev (3m)1.36%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.88%
Revenue NY rev (1m)0.64%
Revenue NY rev (3m)-4.18%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.94
P/FCF N/A
P/OCF N/A
P/B 1.29
P/tB 1.49
EV/EBITDA N/A
EPS(TTM)-0.54
EYN/A
EPS(NY)-0.2
Fwd EYN/A
FCF(TTM)-1
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS2.97
BVpS2.17
TBVpS1.87
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 7.48%
ROE 20.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 15.08%
GM 41.01%
FCFM N/A
ROA(3y)-15.85%
ROA(5y)-14.17%
ROE(3y)-50.34%
ROE(5y)-55.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.2%
GM growth 5Y-7.06%
F-Score5
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 1.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 83.96%
Cap/Sales 6.63%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.61
Quick Ratio 2.14
Altman-Z -0.12
F-Score5
WACC8.67%
ROIC/WACCN/A
Cap/Depr(3y)101.58%
Cap/Depr(5y)231.17%
Cap/Sales(3y)9.04%
Cap/Sales(5y)14.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-184.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.63%
EPS Next Y-597.38%
EPS Next 2Y-69.87%
EPS Next 3Y119.91%
EPS Next 5YN/A
Revenue 1Y (TTM)10.32%
Revenue growth 3Y-21.31%
Revenue growth 5Y6.09%
Sales Q2Q%50.31%
Revenue Next Year6.9%
Revenue Next 2Y17.55%
Revenue Next 3Y26.72%
Revenue Next 5Y24.84%
EBIT growth 1Y82.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-262.99%
EBIT Next 3Y35.74%
EBIT Next 5Y30.38%
FCF growth 1Y61.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y66.85%
OCF growth 3YN/A
OCF growth 5YN/A